Company news
Lexicon Pharmaceuticals, Inc. news in 2023
Lexicon Pharmaceuticals, Inc.'s news releases, calls and decks from 2023, newest first.
Lexicon Pharmaceuticals To Participate In The 42nd Annual JPMorgan Healthcare Conference
December 20, 2023
Lexicon Enrolls First Patient in Phase 2b Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
November 29, 2023
Lexicon Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference and the 6th Annual Evercore ISI HealthCONx Conference
November 21, 2023
INPEFA® (sotagliflozin) Use Associated With Early Clinical Benefit in Heart Failure and Atherosclerotic Events in Analysis of Clinical Data
November 11, 2023
Lexicon Pharmaceuticals to Participate in the Jefferies London Healthcare Conference
November 9, 2023
Lexicon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
November 7, 2023
Lexicon Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call and Webcast on November 8, 2023
November 2, 2023
Data on Early Clinical Benefit for INPEFA® (Sotagliflozin) Will Be Among Five Lexicon-Sponsored Presentations at the American Heart Association Scientific Sessions 2023
November 1, 2023
INPEFA® (Sotagliflozin) Receives Coverage From Express Scripts on Its Basic and High Performance Formularies for Commercially Insured Patients
October 31, 2023
Lexicon Strengthens Management Team With Two New Executives
October 30, 2023
New Data Relating to Sotagliflozin to be Presented at the American Society of Nephrology (ASN) Kidney Week 2023 Annual Meeting
October 29, 2023
Data From Two Studies Demonstrating Positive Financial Impact of INPEFA® (Sotagliflozin) to be Presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting
October 16, 2023
Data Demonstrating Financial Impact of INPEFA® (Sotagliflozin) to be Presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting
October 10, 2023
Tom Garner Joins Lexicon as Senior Vice President and Chief Commercial Officer
October 8, 2023
INPEFA® (Sotagliflozin) Receives Preferred Formulary Status With Express Scripts For Medicare Patients
October 8, 2023
Lexicon to Present Post Hoc Analysis of Scored Clinical Trial at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2023
September 27, 2023
Lexicon to Present Study Results Relating to Sotagliflozin and LX9211 at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD)
September 25, 2023
Lexicon Pharmaceuticals to Participate in the H.C. Wainwright & Co. 25th Annual Global Investment Conference
September 6, 2023
Lexicon Announces Series of Presentations Relating to LX9211, Its Investigational Drug for the Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)
September 6, 2023
Lexicon to Present Analyses of INPEFA™ (sotagliflozin) Clinical Study Results and Changing Patterns of Heart Failure Diagnoses at the European Society of Cardiology (ESC) Congress 2023
August 20, 2023
Published Analysis of Sotagliflozin (INPEFA(TM)) Clinical Data Demonstrates Significant Reductions in the Risk of Hospital Readmissions for Heart Failure
August 7, 2023
Lexicon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
August 2, 2023
Lexicon Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call and Webcast on August 3, 2023
July 27, 2023
Lexicon Elects Diane E. Sullivan to Board of Directors
July 27, 2023
Lexicon Announces Planned Advancement of LX9211 Into Late-Stage Development
June 22, 2023
Lexicon to Present Study Results Relating to LX9211 and INPEFA™ (Sotagliflozin) at the American Diabetes Association’s 83rd Scientific Sessions
June 19, 2023
UPDATE: Lexicon Announces FDA Approval of INPEFA™ (sotagliflozin) for Treatment of Heart Failure
June 14, 2023
Lexicon Pharmaceuticals to Participate in the Jefferies 2023 Global Healthcare Conference
June 5, 2023
Lexicon Announces Closing of Public Offering and Concurrent Private Placement, Including Full Exercise of Options to Purchase Additional Shares
June 4, 2023
Lexicon Announces Pricing of $125 Million Public Offering and Concurrent Private Placement
May 31, 2023
Lexicon Announces FDA Approval of INPEFA™ (sotagliflozin) for Treatment of Heart Failure
May 25, 2023
New Analysis Finds Sotagliflozin to Be a Cost-Effective Treatment at Commonly Accepted Willingness-to-Pay Threshold in Patients with Worsening Heart Failure
May 9, 2023
Lexicon Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
May 1, 2023
Lexicon Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call and Webcast on May 2, 2023
April 27, 2023
Lexicon To Present Results From LX9211 Phase 2 Trial In Postherpetic Neuralgia At The 2023 American Academy Of Neurology (AAN) Annual Meeting And The British Pain Society (BPS) 56th Annual Scientific Meeting 2023
April 20, 2023
Lexicon Pharmaceuticals to Participate in The 22nd Annual Needham Virtual Healthcare Conference
April 16, 2023
Lexicon Reveals “INTO THE DARK” Awareness Campaign About Vulnerable and Dangerous Period of Time Faced by Heart Failure Patients Following Hospitalization
March 3, 2023
Lexicon Pharmaceuticals Reports Fourth Quarter 2022 Financial Results and Provides Business Update
March 1, 2023
Calls in 2023
Decks in 2023
- Investor Presentation (November 2023)
Investor deck · 27 slides · November 2023
- Investor Presentation (August 2023)
Investor deck · 26 slides · August 2023